Use of recombinant activated factor VII after axillofemoral bypass grafting.
Recombinant activated factor VII (rFVIIa) is a powerful prohaemostatic agent that theoretically predisposes to thrombosis after peripheral vascular surgery. We report the use of rFVIIa to reduce bleeding in a patient after axillofemoral bypass grafting for ruptured aorto-iliac pseudoaneurysm. Despite the increased risk of thrombosis, the patient made an uneventful recovery with preserved graft patency. The favourable result suggests that rFVIIa should be considered even in vascular surgical patients, if the risks of continued bleeding outweigh those of thrombosis. Better risk estimation is only possible if reports of rFVIIa use in vascular patients continue to appear and through controlled trials.
Cheng
C A Y
CA
Department of Anaesthesia and Intensive Care, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, NT.
Ho
A M H
AM
D017541:Aneurysm, False / Q000601:surgery; D017544:Aortic Aneurysm, Abdominal / Q000601:surgery; D001807:Blood Vessel Prosthesis; D005167:Factor VII / Q000627:therapeutic use*; D015942:Factor VIIa; D006490:Hemostatics / Q000627:therapeutic use*; D006801:Humans; D017543:Iliac Aneurysm / Q000601:surgery; D008297:Male; D008875:Middle Aged; D019106:Postoperative Hemorrhage / Q000188:drug therapy*; D011994:Recombinant Proteins / Q000627:therapeutic use; D014656:Vascular Surgical Procedures
D006490:Hemostatics; D011994:Recombinant Proteins; D005167:Factor VII; C103587:recombinant FVIIa; D015942:Factor VIIa